My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

98.07 +2.01 (+2.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Which stocks are gapping on Wednesday? ↗

July 09, 2025

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Wondering what's happening in today's after-hours session? ↗

July 08, 2025

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

8 Analysts Have This To Say About Rhythm Pharmaceuticals ↗

June 26, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years ↗

June 05, 2025

Via Benzinga

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know ↗

May 29, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts ↗

March 07, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗

May 22, 2025

RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors.

Via Chartmill

Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) ↗

May 07, 2025

Via Benzinga

These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗

April 13, 2025

Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.

Via Benzinga

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday ↗

April 08, 2025

Via Benzinga

7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know ↗

February 19, 2025

Via Benzinga

Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals ↗

December 20, 2024

Via Benzinga

Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

April 08, 2025

Via Benzinga

Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish ↗

April 07, 2025

CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.

Via Stocktwits

Topics Government

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder ↗

April 07, 2025

Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.

Via Benzinga

Analyst Expectations For Rhythm Pharmaceuticals's Future ↗

March 24, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts ↗

November 25, 2024

Via Benzinga

What's Next: Rhythm Pharmaceuticals's Earnings Preview ↗

November 04, 2024

Via Benzinga

Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know ↗

October 25, 2024

Via Benzinga

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential ↗

December 20, 2024

Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion

Via Benzinga

Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals ↗

October 07, 2024

Via Benzinga

What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals ↗

September 18, 2024

Via Benzinga

RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 ↗

August 06, 2024

RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts ↗

July 25, 2024

Via Benzinga

The 3 Best Nasdaq Stocks to Buy in May 2024 ↗

May 07, 2024

Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May.

Via InvestorPlace

Analyst Expectations For Rhythm Pharmaceuticals's Future ↗

April 26, 2024

Via Benzinga

RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson ↗

April 19, 2024

The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.